News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma
Ilya Tsimafeyeu/bucare.org
Jun 26, 2025, 08:50

Ilya Tsimafeyeu: Promising Results for the Bevacizumab plus Erlotinib in Hereditary and Sporadic Papillary Renal Cell Carcinoma

Ilya Tsimafeyeu, Director at the Bureau of Cancer Re­search, shared a post on Facebook:

“Long-term follow-up has shown promising results for the combination of bevacizumab and erlotinib in hereditary and sporadic papillary renal cell carcinoma.
I treated two patients with HLRCC-related kidney cancer, and both experienced durable partial responses to bev plus erlo.
Additionally, I prescribed this combination to a patient with metastatic FH-deficient papillary RCC, who achieved a complete response. I can strongly recommend!”

Title: Bevacizumab and Erlotinib in Hereditary and Sporadic Papillary Kidney Cancer

Journal: NEJM

Authors: Ramaprasad Srinivasan, Sandeep Gurram, Eric A. Singer, Abhinav Sidana, Munjid Al Harthy, Mark W. Ball, Julia C. Friend, Lisa Mac, Erin Purcell, Cathy D. Vocke, Christopher J. Ricketts, Heidi H. Kong, Edward W. Cowen, Ashkan A. Malayeri, Joanna H. Shih, Maria J. Merino, W. Marston Linehan

Read the full article.

Bevacizumab

More posts featuring Ilya Tsimafeyeu on OncoDaily.

Bevacizumab cancer Erlotinib hereditary papillary renal cell carcinoma HLRCC-related kidney cancer Ilya Tsimafeyeu kidney cancer OncoDaily Oncology papillary renal cell carcinoma sporadic papillary renal cell carcinoma
Special Coverage
Opinion
Jun 26, 2025, 11:16
Elena Castro Discussed Positive Findings from the CAPTURE and AMPLITUDE trials in the ESMO Daily Reporter - ESMO
Blog
Jun 26, 2025, 11:14
Sumanta Pal: Had a Blast Chatting with Walter Stadler and Alan H Bryce at ASCO25 for the City of Hope Podcast
Blog
Jun 26, 2025, 10:44
How Can EU Cancer Policy Best Support Cyprus? - European Cancer Organisation
Insight
Jun 26, 2025, 10:37
Beth Faiman: Hot Off the Presses - NCCN Guidelines v1.2026 Now Online
Opinion
Jun 26, 2025, 10:26
Rahul Banerjee: One of the Most Eloquent Arguments About 2nd-line CAR-T in Multiple Myeloma I've Ever Seen
Blog
Jun 26, 2025, 10:06
Jed Hansen: Nearly Half of All Rural Hospitals in Nebraska Operated at a Loss in 2024
Radiotherapy
Jun 26, 2025, 09:53
Radiotherapy In Pets: Healing Beams for Animals
Science
Jun 26, 2025, 09:52
Routine Childhood Vaccines Saved 154 Million Lives in the Past 50 Years - The Lancet Group
Blog
Jun 26, 2025, 09:48
Andrew M. Evens: Playing With 5-year-old Sirena, Who is Battling Leukemia, Was the Best Part of the Day
Blog
Jun 26, 2025, 09:47
Jan Hirsch: ACPE Board Voted to Grant Full Accreditation Status to the UC Irvine Doctor of Pharmacy Program
Blog
Jun 26, 2025, 09:37
Tune in for The Second Session of the Community 365 Roundtable on Addressing the Challenges of Women and Cancer - ECO
Blog
Jun 26, 2025, 09:36
NCDconnect and ACT for Children: Closing the Paediatric Cancer Gap